Healthy News

Improving & maintaining heart health after pregnancy may reduce the risk of future CVD

Research Highlights:

  • An analysis of health records for almost 110,000 women in the UK found that women with poor cardiovascular health after pregnancy or who experienced adverse pregnancy outcomes, including high blood pressure, gestational diabetes and/or pre-term birth, had a significantly higher long-term risk of developing cardiovascular disease.
  • Among women with adverse pregnancy outcomes, those who maintained better cardiovascular health after pregnancy had cardiovascular disease risk similar to women who had no history of pregnancy complications.

Embargoed until 1:30 pm CT/2:30 pm ETThursday, March 21, 2024

CHICAGO, March 21, 2024 — Women with a history of adverse pregnancy complications are at significantly higher risk of developing heart disease but can reduce their risk by maintaining optimal heart health after pregnancy, according to preliminary research to be presented at the American Heart Association’s Epidemiology and Prevention│Lifestyle and Cardiometabolic Scientific Sessions 2024, March 18- 21, in Chicago. The meeting offers the latest science on population-based health and wellness and implications for lifestyle.

“Previous studies have shown that women with a history of adverse pregnancy outcomes tend to have a higher risk of developing cardiovascular disease later in life,” said lead study author Frank Qian, MD, MPH, a cardiovascular medicine fellow at Boston Medical Center and clinical instructor at the Boston University Chobanian & Avedisian School of Medicine. “However, it is unknown how much of this increased cardiovascular disease risk can be potentially modified by healthy lifestyle behaviors.”

Adverse pregnancy outcomes examined in this study included placental abruption, gestational diabetes, small size for gestational age, pre-term birth and/or hypertensive disorders of pregnancy, defined as preeclampsia or gestational hypertension. Additionally, according to the Association’s 2021 statement on Adverse Pregnancy Outcomes and Cardiovascular Disease Risk, many adverse pregnancy outcomes are associated with the future development of CVD risk factors, including hypertension, Type 2 diabetes and dyslipidemia.

In this study, researchers reviewed data from the UK Biobank to evaluate the association between Life’s Essential 8 scores and the development of cardiovascular disease in women with and without a history of adverse pregnancy outcomes. Life’s Essential 8 are key measures defined by the American Heart Association for improving and maintaining optimal cardiovascular health, including healthy diet, physical activity, smoking cessation, healthy sleep habits and managing weight, cholesterol, blood sugar and blood pressure. Cardiovascular health scores range from 0-100, with higher scores indicating better cardiovascular health.

The analysis found significant interactions among adverse pregnancy outcomes, cardiovascular health scores and cardiovascular events during the 13.5-year follow-up period:

  • Women who had better cardiovascular health measures after pregnancy, or Life’s Essential 8 scores higher than 76, had a 57% lower risk of developing cardiovascular disease compared to women with scores below 67.
  • Women who had complications during pregnancy and poor cardiovascular health scores after pregnancy had a 148% increase in the risk of developing cardiovascular disease.
  • Among women with a history of pregnancy complications, those who achieved or maintained high heart health after pregnancy were at a similar risk for heart disease as women without adverse pregnancy outcomes and good cardiovascular health.
  • Women with intermediate and low Life’s Essential 8 scores (scores of 68.2 to 77.5 and below 68.1, respectively) have an elevated risk for heart disease – 25% and 81%, respectively – whether or not they have a prior history of adverse pregnancy outcomes.

“We were most surprised to find that women who had a history of pregnancy complications and were able to achieve and maintain a high level of cardiovascular health after pregnancy significantly reduced their risk of future cardiovascular disease. “They essentially have an equivalent CVD risk to women without a history of adverse pregnancy outcomes who also have high cardiovascular health,” Qian said.

“These findings are important for clinical practice as well as designing public health interventions and policies. We need to identify high-risk women and focus on ensuring they have access to means of improving their lifestyle or treatment to reduce their long-term risk of cardiovascular disease.”

Study background and details:

  • The UK Biobank is a large biomedical database and research resource with health records of about 500,000 adults — enrolled from 2006 until 2010 — who lived in the UK and received health care through the UK’s National Health Service. The researchers accessed the data in April 2023.
  • The study included 2,263 women with a prior diagnosis of adverse pregnancy outcomes and 107,260 women who had no history of complications during pregnancy. None of the participants had cardiovascular disease at the beginning of the study.
  • Mean age of participants at the time of enrollment was 50.2 years among women with a history of adverse pregnancy outcomes and 56.6 years among women without a history of adverse pregnancy outcomes.
  • Over the average 13.5 years of follow-up, 197 cardiovascular disease events were documented in women with a history of adverse pregnancy outcomes.
  • 95.2% of the participants self-identified as white; 4.8% self-identified as other race, which the researchers combined as one group to meet analytical thresholds. Cardiovascular outcomes were not statistically different between the two groups, Qian said.
  • The proportion of women who had an adverse pregnancy outcome and self-identified as non-white was 8.2%, compared to 4.8% of the participants who had no history of an adverse pregnancy outcome.

The study’s limitations included that it was an observational analysis, meaning the findings do not confirm cause and effect, and that more than 94% of the study population from the UK Biobank self-identified as white race, meaning the findings may not be generalizable to people of other races or ethnicities.

“Our study did not include enough women from other diverse races or ethnicities to have to be able to understand how cardiovascular health metrics after an adverse pregnancy outcome may influence long-term CVD risk,” Qian said. “That being said, we observed a trend towards lower risk for cardiovascular disease in women who maintained better cardiovascular health after pregnancy, so these improvements in cardiovascular health should also be beneficial to women of other races and ethnicities, although more research is needed to confirm this hypothesis.”

Nieca Goldberg, MD, a clinical associate professor of medicine at NYU Grossman School of Medicine, medical director of Atria NY and an American Heart Association volunteer expert who was not involved in the study, said, “This is an important study because it indicates a role for prevention to lower heart disease risk in women who have pregnancy related disorders of preeclampsia, pre-term birth and gestational diabetes,” she said. “When applying Life’s Essential 8 risk scores, those women with the lowest scores were at higher risk for cardiovascular disease. We need to encourage health care professionals to integrate Life’s Essential 8 into clinical practice to improve heart health in women with and without pregnancy-related disorders. In addition, we need additional research to evaluate the benefits of Life’s Essential 8 in diverse populations of women.”

Co-authors, their disclosures and funding sources are listed in the abstract.

Statements and conclusions of studies that were presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are here.

Additional Resources:


The American Heart Association’s EPI|Lifestyle Scientific Sessions 2024 is the world’s premiere meeting dedicated to the latest advances in population-based science. The 2024 meeting is in-person only, Monday through Thursday, March 18-21 at the Hilton Chicago. The primary goal of the meeting is to promote the development and application of translational and population science to prevent heart disease and stroke and foster cardiovascular health. The sessions focus on risk factors, obesity, nutrition, physical activity, genetics, metabolism, biomarkers, subclinical disease, clinical disease, healthy populations, global health and prevention-oriented clinical trials. The Councils on Epidemiology and Prevention and Lifestyle and Cardiometabolic Health (Lifestyle) jointly planned the EPI|Lifestyle Scientific Sessions 2024. Follow the conference on Twitter at #EPILifestyle24.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for a century. During 2024 – our Centennial year – we celebrate our rich 100-year history and accomplishments. As we forge ahead into our second century of bold discovery and impact, our vision is to advance health and hope for everyone, everywhere. Connect with us on, Facebook, X or by calling 1-800-AHA-USA1.

For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173; [email protected]

John Arnst: [email protected], 214-706-1060

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and

Recommended Articles